Skip to content
HowShorted

Phathom Pharmaceuticals, Inc. short interest in 2022

In 2022, Phathom Pharmaceuticals, Inc.'s disclosed short interest ran from 11.19% of shares outstanding on 14 Jan 2022 to 4.55% on 30 Dec 2022, a change of -6.64 percentage points. The year's high was 14.69% on 31 Aug 2022 and its low 3.81% on 15 Dec 2022, averaging 8.43% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 34.19 days on 28 Feb 2022. Full history: Phathom Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Phathom Pharmaceuticals, Inc. in 2022

2022 in figures

Start of year
11.19% (14 Jan 2022)
End of year
4.55% (30 Dec 2022)
Change
-6.64 pp
High
14.69% (31 Aug 2022)
Low
3.81% (15 Dec 2022)
Average
8.43%
Highest days to cover
34.19 (28 Feb 2022)
SEC filings marked
8

Every report in 2022

Phathom Pharmaceuticals, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202211.19%28.37
31 Jan 202210.89%27.97
15 Feb 202211.11%21.28
28 Feb 202211.51%34.19
15 Mar 20225.71%17.3710-K filed, results (8-K)
31 Mar 20226.59%16.77
14 Apr 20227.75%17.84
29 Apr 20227.97%25.61
13 May 20227.93%5.6910-Q filed, results (8-K)
31 May 20228.09%8.87
15 Jun 20228.28%14.31
30 Jun 20228.25%9.92
15 Jul 20228.27%27.03
29 Jul 20228.10%34.06
15 Aug 202214.01%9.6410-Q filed, results (8-K)
31 Aug 202214.69%31.12
15 Sep 202214.55%26.43
30 Sep 202211.29%8.69
14 Oct 20225.12%17.95
31 Oct 20224.69%11.76
15 Nov 20224.06%11.9210-Q filed, results (8-K)
30 Nov 20223.85%14.02
15 Dec 20223.81%12.02
30 Dec 20224.55%12.05

See also: Phathom Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.